The clot thickens (or not).
In this issue of Blood, Gratacap and colleagues analyze the effects of the multikinase inhibitor dasatinib on platelets, helping to explain the occurrence of bleeding related to its use for CML patients resistant to or intolerant of imatinib.(1) In addition, by virtue of careful experimentation using multiple functional platelet assays, these authors are paving the way for the development of kinase inhibitors as antithrombotic agents.